BACKGROUND: The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) recently published an equation for estimated glomerular filtration rate (eGFR) using the same variables (serum creatinine level, age, sex, and race) as the Modification of Diet in Renal Disease (MDRD) Study equation. Although the CKD-EPI equation estimates GFR more precisely compared with the MDRD Study equation, whether this equation improves risk prediction is unknown. STUDY DESIGN: Prospective cohort study, the Atherosclerosis Risk in Communities (ARIC) Study. SETTING & PARTICIPANTS: 13,905 middle-aged participants without a history of cardiovascular disease with median follow-up of 16.9 years. PREDICTOR: eGFR. OUTCOMES & MEASUREMENTS: We compared the association of eGFR in categories (>or=120, 90-119, 60-89, 30-59, and <30 mL/min/1.73 m(2)) using the CKD-EPI and MDRD Study equations with risk of incident end-stage renal disease, all-cause mortality, coronary heart disease, and stroke. RESULTS: The median value for eGFR(CKD-EPI) was higher than that for eGFR(MDRD) (97.6 vs 88.8 mL/min/1.73 m(2); P < 0.001). The CKD-EPI equation reclassified 44.9% (n = 3,079) and 43.5% (n = 151) of participants with eGFR(MDRD) of 60-89 and 30-59 mL/min/1.73 m(2), respectively, upward to a higher eGFR category, but reclassified no one with eGFR(MDRD) of 90-119 or <30 mL/min/1.73 m(2), decreasing the prevalence of CKD stages 3-5 from 2.7% to 1.6%. Participants with eGFR(MDRD) of 30-59 mL/min/1.73 m(2) who were reclassified upward had lower risk compared with those who were not reclassified (end-stage renal disease incidence rate ratio, 0.10 [95% CI, 0.03-0.33]; all-cause mortality, 0.30 [95% CI, 0.19-0.48]; coronary heart disease, 0.36 [95% CI, 0.21-0.61]; and stroke, 0.50 [95% CI, 0.24-1.02]). Similar results were observed for participants with eGFR(MDRD) of 60-89 mL/min/1.73 m(2). More frequent reclassification of younger, female, and white participants explained some of these trends. Net reclassification improvement in participants with eGFR < 120 mL/min/1.73 m(2) was positive for all outcomes (P < 0.001). LIMITATIONS: Limited number of cases with eGFR < 60 mL/min/1.73 m(2) and no measurement of albuminuria. CONCLUSIONS: The CKD-EPI equation more appropriately categorized individuals with respect to long-term clinical risk compared with the MDRD Study equation, suggesting improved clinical usefulness in this middle-aged population. Copyright 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
BACKGROUND: The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) recently published an equation for estimated glomerular filtration rate (eGFR) using the same variables (serum creatinine level, age, sex, and race) as the Modification of Diet in Renal Disease (MDRD) Study equation. Although the CKD-EPI equation estimates GFR more precisely compared with the MDRD Study equation, whether this equation improves risk prediction is unknown. STUDY DESIGN: Prospective cohort study, the Atherosclerosis Risk in Communities (ARIC) Study. SETTING & PARTICIPANTS: 13,905 middle-aged participants without a history of cardiovascular disease with median follow-up of 16.9 years. PREDICTOR: eGFR. OUTCOMES & MEASUREMENTS: We compared the association of eGFR in categories (>or=120, 90-119, 60-89, 30-59, and <30 mL/min/1.73 m(2)) using the CKD-EPI and MDRD Study equations with risk of incident end-stage renal disease, all-cause mortality, coronary heart disease, and stroke. RESULTS: The median value for eGFR(CKD-EPI) was higher than that for eGFR(MDRD) (97.6 vs 88.8 mL/min/1.73 m(2); P < 0.001). The CKD-EPI equation reclassified 44.9% (n = 3,079) and 43.5% (n = 151) of participants with eGFR(MDRD) of 60-89 and 30-59 mL/min/1.73 m(2), respectively, upward to a higher eGFR category, but reclassified no one with eGFR(MDRD) of 90-119 or <30 mL/min/1.73 m(2), decreasing the prevalence of CKD stages 3-5 from 2.7% to 1.6%. Participants with eGFR(MDRD) of 30-59 mL/min/1.73 m(2) who were reclassified upward had lower risk compared with those who were not reclassified (end-stage renal disease incidence rate ratio, 0.10 [95% CI, 0.03-0.33]; all-cause mortality, 0.30 [95% CI, 0.19-0.48]; coronary heart disease, 0.36 [95% CI, 0.21-0.61]; and stroke, 0.50 [95% CI, 0.24-1.02]). Similar results were observed for participants with eGFR(MDRD) of 60-89 mL/min/1.73 m(2). More frequent reclassification of younger, female, and white participants explained some of these trends. Net reclassification improvement in participants with eGFR < 120 mL/min/1.73 m(2) was positive for all outcomes (P < 0.001). LIMITATIONS: Limited number of cases with eGFR < 60 mL/min/1.73 m(2) and no measurement of albuminuria. CONCLUSIONS: The CKD-EPI equation more appropriately categorized individuals with respect to long-term clinical risk compared with the MDRD Study equation, suggesting improved clinical usefulness in this middle-aged population. Copyright 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Authors: Josef Coresh; Brad C Astor; Geraldine McQuillan; John Kusek; Tom Greene; Frederick Van Lente; Andrew S Levey Journal: Am J Kidney Dis Date: 2002-05 Impact factor: 8.860
Authors: Lloyd E Chambless; Aaron R Folsom; A Richey Sharrett; Paul Sorlie; David Couper; Moyses Szklo; F Javier Nieto Journal: J Clin Epidemiol Date: 2003-09 Impact factor: 6.437
Authors: Lesley A Stevens; Josef Coresh; Harold I Feldman; Tom Greene; James P Lash; Robert G Nelson; Mahboob Rahman; Amy E Deysher; Yaping Lucy Zhang; Christopher H Schmid; Andrew S Levey Journal: J Am Soc Nephrol Date: 2007-09-12 Impact factor: 10.121
Authors: Andrew D Rule; Hiie M Gussak; Gregory R Pond; Erik J Bergstralh; Mark D Stegall; Fernando G Cosio; Timothy S Larson Journal: Am J Kidney Dis Date: 2004-01 Impact factor: 8.860
Authors: Mark J Sarnak; Andrew S Levey; Anton C Schoolwerth; Josef Coresh; Bruce Culleton; L Lee Hamm; Peter A McCullough; Bertram L Kasiske; Ellie Kelepouris; Michael J Klag; Patrick Parfrey; Marc Pfeffer; Leopoldo Raij; David J Spinosa; Peter W Wilson Journal: Circulation Date: 2003-10-28 Impact factor: 29.690
Authors: Ervin R Fox; Tandaw E Samdarshi; Solomon K Musani; Michael J Pencina; Jung Hye Sung; Alain G Bertoni; Vanessa Xanthakis; Pelbreton C Balfour; Satya S Shreenivas; Carolyn Covington; Philip R Liebson; Daniel F Sarpong; Kenneth R Butler; Thomas H Mosley; Wayne D Rosamond; Aaron R Folsom; David M Herrington; Ramachandran S Vasan; Herman A Taylor Journal: JAMA Cardiol Date: 2016-04-01 Impact factor: 14.676
Authors: Nawar M Shara; Hong Wang; Mihriye Mete; Yaman Rai Al-Balha; Nameer Azalddin; Elisa T Lee; Nora Franceschini; Stacey E Jolly; Barbara V Howard; Jason G Umans Journal: Am J Kidney Dis Date: 2012-07-25 Impact factor: 8.860